Fennec Pharmaceuticals
Open
$6.49
Prev. Close
$6.49
High
$6.50
Low
$6.47
Market Snapshot
$176.01M
-18.1
-0.02
$47.54M
35
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
emptyResult
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Recently from Cashu
Fennec Pharmaceuticals: Key Developments and Future Outlook for Stock Performance
Please provide the text you would like me to summarize, and I will create a 300-word paragraph for you.
Fennec Pharmaceuticals: Key Updates and Insights on Stock Performance and Future Prospects
Please provide the text you would like me to summarize, and I will create a 300-word paragraph for you.
Fennec Pharmaceuticals Stock Analysis: Key Insights and Future Prospects
Please provide the content you would like me to summarize, and I will create a 300-word article for you.
Fennec Pharmaceuticals Eyes Key Earnings Report Amid Market Scrutiny and Growth Potential
Fennec Pharmaceuticals Prepares for Key Earnings Report Amidst Industry Scrutiny Fennec Pharmaceuticals is on the brink of releasing its quarterly earnings report on August 14, 2025, a development tha…